Now showing items 11-20 of 51
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer All patients provided informed consent.
(Wiley Subscription Services, Inc., A Wiley Company, 2008-09-01)
BACKGROUND This open-label, multicenter, dose-escalation study evaluated multiple dose levels of immunotherapy in patients with metastatic hormone-refractory prostate cancer (HRPC). The immunotherapy, based on the GVAX ...
Features of the metabolic syndrome and prostate cancer in African-American men
(Wiley Subscription Services, Inc., A Wiley Company, 2007-03-01)
BACKGROUND. Metabolic syndrome refers to a cluster of conditions that includes hypertension, dyslipidemia, central adiposity, and high blood glucose levels. Over the past decade, a growing body of literature suggests that ...
Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI)
(Wiley Subscription Services, Inc., A Wiley Company, 2007-05-01)
BACKGROUND. Health-related quality of life (HRQOL) has not been adequately measured in bladder cancer. A recently developed reliable and disease-specific quality of life instrument (Bladder Cancer Index, BCI) was used to ...
Chemotherapy in patients with prostate specific antigen–only disease after primary therapy for prostate carcinoma
(John Wiley & Sons, Inc., 2001-06-01)
BACKGROUND A Phase II study was initiated to evaluate the effectiveness of an oral regimen of etoposide and estramustine in patients with early recurrent prostate carcinoma. METHODS Patients with early recurrent prostate ...
Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone
(Kluwer Academic Publishers; Springer Science+Business Media, 2001-12)
The majority of men with progressive prostate cancer develop metastases with the skeleton being the most prevalent metastatic site. Unlike many other tumors that metastasize to bone and form osteolytic lesions, prostate ...
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma
(Wiley Subscription Services, Inc., A Wiley Company, 2009-09-15)
BACKGROUND: The activity and safety of vinflunine was evaluated in patients with locally advanced or metastatic urothelial carcinoma (UC) who developed disease progression within 12 months of platinum-containing chemotherapy. ...
Chromosome 8q24 markers: Risk of early-onset and familial prostate cancer
(Wiley Subscription Services, Inc., A Wiley Company, 2008-06-15)
Recent admixture mapping and linkage/association studies have implicated an ∼1 Mb region on chromosome 8q24 in prostate cancer susceptibility. In a subsequent follow-up investigation, Haiman et al. (Nat Genet 2007;39:638-44) ...
The times they are a-changin' (Bob Dylan, 1964) See related original article on pages 000–000, this issue.
(Wiley Subscription Services, Inc., A Wiley Company, 2007-12-01)
No abstract.
The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft
(Kluwer Academic Publishers; Springer Science+Business Media, 2004-12)
Osteoprotegerin (OPG) plays a central role in controlling bone resorption. Exogenous administration of OPG has been shown to be effective in preventing osteolysis and limiting the growth of osteolytic metastasis. The ...
Diffusion of surgical innovation among patients with kidney cancer
(Wiley Subscription Services, Inc., A Wiley Company, 2008-04-15)
BACKGROUND Despite their potential benefits to patients with kidney cancer, the adoption of partial nephrectomy and laparoscopy has been gradual and asymmetric. To clarify whether this trend reflects differences in kidney ...